Objective
C-type lectin domain family 2, member D (CLEC2D) is implicated in the immune response. Pre-eclampsia and HIV infection have opposing immune responses. In view of the high prevalence of HIV infection and pre-eclampsia in South Africa, this study assessed the placental immuno-expression of CLEC2D in HIV associated pre-eclampsia.
Method
Placental tissue was obtained from 60 pregnancies which were categorized according to pregnancy type (pre-eclamptic or normotensive) and HIV status (positive or negative). Immunohistochemistry and morphometric image analysis were used to evaluate placental CLEC2D immuno-expression.
Results
CLEC2D expression was significantly decreased in the conducting villi of pre-eclamptic
vs
normotensive placentae (
p
= 0.0418) but was increased in the exchange villi, albeit non-significant (
p
= 0.4948). HIV positive status intensified placental CLEC2D immuno-expression in conducting (
p
= 0.0312) and exchange (
p
= 0.0025) villi. CLEC2D expression was significantly different in exchange
vs
conducting villi (p < 0.0001) and across study groups (
p
= 0.0003). Normotensive; HIV negative placentae (control) had a non-significant difference in CLEC2D expression across villi types, however significant difference was noted within the remaining groups: normotensive; HIV positive (
p
< 0.05), pre-eclamptic; HIV positive (
p
< 0.01 and pre-eclamptic; HIV negative (
p
< 0.001).
Conclusion
The contrasting expression of CLEC2D in HIV infection and pre-eclampsia is demonstrative of the immunosuppressive and pro-inflammatory roles of the respective pathologies. However, this implication may be confounded by highly active anti-retroviral treatment (HAART).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.